Reported US Post Covid vax Myocarditis Cases Dec 2020 – Aug 2021
What is the risk of myocarditis after mRNA-based COVID-19 vaccination in the US?
Findings
In this descriptive study of 1626 cases of myocarditis in a national passive reporting system, the crude reporting rates within 7 days after vaccination exceeded the expected rates across multiple age and sex strata.
The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively).
Meaning
Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men.
Abstract
Importance Vaccination against COVID-19 provides clear public health benefits, but vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID-19 vaccination are unclear.
Objective
To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US.
Design, Setting, and Participants
Descriptive study of reports of myocarditis to the Vaccine Adverse Event Reporting System (VAERS) that occurred after mRNA-based COVID-19 vaccine administration between December 2020 and August 2021 in 192 405 448 individuals older than 12 years of age in the US; data were processed by VAERS as of September 30, 2021.
Exposures
Vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna).
Main Outcomes and Measures
Reports of myocarditis to VAERS were adjudicated and summarized for all age groups. Crude reporting rates were calculated across age and sex strata. Expected rates of myocarditis by age and sex were calculated using 2017-2019 claims data. For persons younger than 30 years of age, medical record reviews and clinician interviews were conducted to describe clinical presentation, diagnostic test results, treatment, and early outcomes.
Results
Among 192,405,448 persons receiving a total of 354,100,845 mRNA-based COVID-19 vaccines during the study period, there were 1991 reports of myocarditis to VAERS and 1626 of these reports met the case definition of myocarditis.
Of those with myocarditis, the median age was 21 years (IQR, 16-31 years) and the median time to symptom onset was 2 days (IQR, 1-3 days). Males comprised 82 percent of the myocarditis cases for whom sex was reported. The crude reporting rates for cases of myocarditis within 7 days after COVID-19 vaccination exceeded the expected rates of myocarditis across multiple age and sex strata.
The rates of myocarditis were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively).
There were 826 cases of myocarditis among those younger than 30 years of age who had detailed clinical information available; of these cases, 792 of 809 (98 percent) had elevated troponin levels, 569 of 794 (72 percent) had abnormal electrocardiogram results, and 223 of 312 (72 percent) had abnormal cardiac magnetic resonance imaging results.
Approximately 96 percent of persons (784/813) were hospitalized and 87 percent (577/661) of these had resolution of presenting symptoms by hospital discharge. The most common treatment was nonsteroidal anti-inflammatory drugs (589/676; 87 percent).
Conclusions and Relevance
Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men. This risk should be considered in the context of the benefits of COVID-19 vaccination.
See more here: jamanetwork.com
Please Donate Below To Support Our Ongoing Work To Expose The Lies About COVID19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.
GM
| #
This was a report on the adverse events of the Covid-19 Vaccine shots. There are numerous articles today on the many serious AE’s that these shots are causing, without even discussing all the deaths from them. Where are the actual scientific studies showing, as the article says “Vaccination against COVID-19 provides clear public health benefits?” Oh, right, the companies like Pfizer want to hide their scientific data from the public for as long as 75 years. So these words of safety that accompany almost every article are nothing more than propaganda! We can see that millions are suffering from these shots. And anyone writing that these shots are “safe and effective” needs to be taken to task for saying that. Where is your proof that they are safe and effective? As you write on how they are just the opposite.
Reply
Squidly
| #
Spot on!
Reply
Brian James
| #
February 20, 2022 68,000% Increase in Strokes as FDA and NIH Secretly Study Reports of Neurological Injuries After COVID-19 Vaccines
A team at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), meanwhile, started seeing patients reporting vaccine injuries for a study in early 2021 after receiving complaints shortly after the vaccines were made available. A portion of the patients was examined in person at the Bethesda, Maryland, facility.
https://healthimpactnews.com/2022/79000-increase-in-strokes-as-fda-and-hih-secretly-study-reports-of-neurological-injuries-after-covid-19-vaccines/
Reply